Form 4: Inogen EVP, CFO & Treasurer Michael J. Bourque Reports Transactions in Company Stock

Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc, reports acquisition and disposal of company stock, including transactions related to restricted stock units and employee stock purchase plan.

Summary

• Michael J. Bourque, the EVP, CFO & Treasurer of Inogen Inc, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2025, Bourque acquired 600 shares of common stock through the company's Employee Stock Purchase Plan at a price of $8.33 per share.
• Also on March 1, 2025, 25,000 shares were acquired through the exercise of restricted stock units.
• Additionally, 9,838 shares were withheld to cover tax liabilities related to the vesting of a portion of a time-based restricted stock unit award.
• 47,625 shares were earned and vested on March 1, 2025, based on the achievement of financial performance conditions for the 2024 fiscal year.
• 18,741 shares were withheld to cover tax liabilities related to the 2023 performance-based restricted stock unit award that vested on March 1, 2025.
• On March 3, 2025, Bourque purchased 3,000 shares at $8.32 per share.
• Bourque also acquired 51,020 restricted stock units on February 28, 2025, which vest in thirds annually starting March 1, 2026.
• Following these transactions, Bourque directly owns 47,646 shares of common stock and 50,000 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports routine stock transactions by an executive, with no explicitly positive or negative implications for the company's performance.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan and open market purchases indicates confidence in the company's future.
• The vesting of performance-based restricted stock units suggests that the company met its financial performance goals for the 2024 fiscal year.

Future Outlook

1/3rd of the restricted stock units granted on February 28, 2025, will vest on March 1, 2026, and 1/3rd will vest annually thereafter, subject to continued service.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Inogen.
• Similar filings are made by executives at companies such as ResMed and Philips, detailing their stock ownership and transactions.
• The vesting schedules for restricted stock units are also typical, often vesting over a period of 3-4 years.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a key executive, providing transparency into insider activity.
• The vesting of performance-based restricted stock units suggests that the company met certain financial goals, which could positively impact shareholder value.

Key Dates